Similar articles

• Missing mifepristone at tribal health facilities serving native Americans.

  Glaser K, Whitehair J. Glaser K, et al. Contraception. 2021 Jul;104(1):36-37. doi: 10.1016/j.contraception.2021.03.027. Epub 2021 Apr 1. Contraception. 2021. PMID: 33811841
• US clinicians' perspectives on how mifepristone regulations affect access to medication abortion and early pregnancy loss care in primary care.

  Srinivasulu S, Yavari R, Brubaker L, Riker L, Prine L, Rubin SE. Srinivasulu S, et al. Contraception. 2021 Jul;104(1):92-97. doi: 10.1016/j.contraception.2021.04.017. Epub 2021 Apr 25. Contraception. 2021. PMID: 33910031
• Trends in medication abortion provision before and after the introduction of mifepristone: A study of the National Abortion Federation's Canadian member services.

  Yalahow A, Doctoroff J, Mark A, Foster AM. Yalahow A, et al. Contraception. 2020 Aug;102(2):119-121. doi: 10.1016/j.contraception.2020.04.012. Epub 2020 Apr 20. Contraception. 2020. PMID: 32325077 Review.
• Risks of and Indications for Mifepristone for Medication Abortion.

  Poehailos K, Gilbert L. Poehailos K, et al. Am Fam Physician. 2022 Jan 1;105(1):5-6. Am Fam Physician. 2022. PMID: 35029956 No abstract available.
• Clinical applications of mifepristone.

  Tang OS, Ho PC. Tang OS, et al. Gynecol Endocrinol. 2006 Dec;22(12):655-9. doi: 10.1080/09513590601005946. Gynecol Endocrinol. 2006. PMID: 17162706 Review.